



An Iterative Approach Guides Discovery of the Fabl Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative Infections

Erica N. Parker,[#] Brett N. Cain,[#] Behnoush Hajian, Rebecca J. Ulrich, Emily J. Geddes, Sulyman Barkho, Hyang Yeon Lee, John D. Williams, Malik Raynor, Diana Caridha, Angela Zaino, Mrinal Shekhar, Kristen A. Muñoz, Kara M. Rzasa, Emily R. Temple, Diana Hunt, Xiannu Jin, Chau Vuong, Kristina Pannone, Aya M. Kelly, Michael P. Mulligan, Katie K. Lee, Gee W. Lau, Deborah T. Hung, and Paul J. Hergenrother*



inhibitors have advanced to clinical trials for Staphylococcus aureus infections but not for infections caused by Gram-negative bacteria. Here, we synthesize a suite of FabI inhibitors whose structures fit permeation rules for Gram-negative bacteria and leverage activity against a challenging panel of Gram-negative clinical isolates as a filter



for advancement. The compound to emerge, called fabimycin, has impressive activity against >200 clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, and does not kill commensal bacteria. X-ray structures of fabimycin in complex with FabI provide molecular insights into the inhibition. Fabimycin demonstrates activity in multiple mouse models of infection caused by Gram-negative bacteria, including a challenging urinary tract infection model. Fabimycin has translational promise, and its discovery provides additional evidence that antibiotics can be systematically modified to accumulate in Gram-negative bacteria and kill these problematic pathogens.

INTRODUCTION

Novel antibiotic classes for infections caused by Gram-positive pathogens have been a success story over the last 20 years, with drugs in the oxazolidinone, mutilin, and lipopeptide classes all having notable clinical or veterinary impact.¹⁻³ Further, there are additional antibiotics moving through clinical trials for Gram-positive infections, including new compound classes and antibiotics that engage unexploited biological targets.⁴ In contrast, there has not been a novel class of antibiotics FDA approved for treatment of Gram-negative pathogens contained within the group of high-priority antibiotic-resistant, nosocomoial pathogens (ESKAPE pathogens^{5,6}) in over 50 years; this situation has led to increased mortality, with these Gramnegative bacteria representing four of the top six pathogens causing antibiotic-associated deaths, and some studies showing that 75% of deaths from drug-resistant pathogens are now caused by Gram-negative bacteria.^{7,8} This discovery void is largely due to the low likelihood that a given compound will accumulate inside Gram-negative bacteria, as their dense

lipopolysaccharide outer membrane and promiscuous efflux pumps work in concert to prevent candidate antibiotics from reaching their target. Recent studies reveal that compounds capable of accumulating inside Gram-negative bacteria often possess certain physicochemical properties,⁹⁻¹¹ explaining why high-throughput screens of millions of compounds have failed to identify Gram-negative active antibiotics.^{12,13}

Encouragingly, the same biological processes that are exploited through antibiotic intervention against Gram-positive bacteria can typically be leveraged to kill Gram-negative bacteria; inhibitors of protein translation, DNA replication, and cell wall biosynthesis have broad-spectrum activity (Grampositive and Gram-negative) provided they can enter the cell and reach their target. However, many other promising biological targets have not yet been leveraged to kill Gramnegative organisms, as the antibiotics that engage these targets

Received: May 19, 2022



do not accumulate in Gram-negative bacteria. One such outstanding target is the enoyl-acyl carrier protein reductase enzyme FabI, which catalyzes the rate-determining step in bacterial fatty acid biosynthesis.¹⁴ A lead compound^{15,16} identified from a biochemical high-throughput screen for FabI inhibition was optimized into Debio-1452 (Figure 1A),




Figure 1. FabI inhibitors. (A) Debio-1452 is highly potent against *S. aureus;* Debio-1452-NH3 retains this potency and gains modest activity against many Gram-negative pathogens. (B) The structure–activity relationship (SAR) of Debio-1452 showing regions amenable to substitution (highlighted in green) and those critical for antibacterial activity (highlighted in red).

the phosphonoxy methyl prodrug version of which (called afabicin) is in Phase 2 clinical trials for infections caused by *Staphylococcus aureus*.¹⁷ While FabI is a promising exploitable target for problematic Gram-negative ESKAPE pathogens, including *Escherichia coli*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*, Debio-1452 does not accumulate inside these cells and is consequently inactive against these bacteria.¹⁸

We recently applied an emerging understanding of the correlation between the physicochemical traits of small molecules and their accumulation in Gram-negative bacteria to design a version of Debio-1452 that is effective against these pathogens.¹⁹ This compound, Debio-1452-NH3 (Figure 1A), has antibacterial activity against Gram-negative clinical isolates and efficacy in mouse infection models, and as such is the first member of this class to have notable Gram-negative antibacterial activity.¹⁹ In efforts to develop a more promising clinical candidate for Gram-negative infections, we now report the use of iterative compound synthesis, clinical isolate testing, and X-ray crystallography to identify fabimycin, a FabI inhibitor with enhanced antibacterial potency, improved in vivo tolerability, and high specificity for pathogenic versus commensal bacteria. Fabimycin shows efficacy in multiple mouse infection models, including a challenging mouse model of urinary tract infection (UTI), acute pneumonia models, and several neutropenic soft tissue models of infection with Gramnegative bacteria.


RESULTS

Identification of Fabimycin and Its Activity against Drug-Resistant Gram-Negative Pathogens. Aided by recently described guidelines for design of Gram-negative penetrant compounds (the eNTRy rules^{9,11,20}), Debio-1452NH3 was discovered through a focused synthetic campaign and subsequent evaluation of just a handful of compounds.¹⁹ However, to advance as a lead candidate, its therapeutic window would need to be widened, as efficacy of Debio-1452-NH3 in murine infection models with Gram-negative pathogens was observed at the maximal tolerated dose (MTD).¹⁹ An objective was set to identify next-generation FabI inhibitors that exhibit greater potency against Gramnegative clinical isolates and better *in vivo* tolerability, expecting that such compounds could then be efficacious even in very challenging models and those of high translational relevance, such as a UTI model.

Our critical path for advancement included the synthesis of compounds and subsequent evaluation of antibacterial activity against Gram-negative clinical isolates to prioritize leads, followed by evaluation of toxicity, pharmacokinetics, and ultimately efficacy in mouse infection models. Compound design was guided by the co-crystal structure of Debio-1452 with FabI (from S. aureus)²¹ and the established structureactivity relationship (SAR) for this compound class, both of which point to the immutability of the N-methyl acrylamide (Econfiguration) and the H-bond donor/acceptor pair on the naphthyridinone ring system that interacts with key amino acid residues within the FabI active site (Figure 1B).²²⁻²⁴ In contrast, the position adjacent to the carbonyl of the naphthyridinone ring was judged to be highly solvent-exposed; additionally, other ring systems were considered as replacements for the benzofuran (Figure 1B). This analysis was instrumental for informing the proper placement of a positively charged amine to facilitate accumulation in Gram-negative bacteria but not disrupt target engagement. Given the X-ray and SAR data, and lessons learned from previous identification of Debio-1452-NH3, priority compounds were envisioned with a variety of amines and ring systems proximal to the carbonyl of the lactam.

A modular and convergent synthesis was designed leveraging a Heck coupling of acrylamide 1 with bromo functionalized acylaminopyridine rings which upon deprotection provided the final compounds (Figure 2). Brominated coupling partners were designed to give final compounds that maintained the necessary N/NH arrangement for engagement with FabI and contained the basic amine required for Gram-negative accumulation. To quickly interrogate the solvent-exposed region of the scaffold adjacent to the lactam carbonyl, ring size and shape were altered. Specifically, a series comprising four-membered ring spirocycles (2-4), six-membered ring spirocycles (5, 6), and azepanones (7-9) was constructed.

The compounds synthesized, shown in Figure 2, were evaluated against Gram-positive and Gram-negative reference strains (S. aureus ATCC 29213 and E. coli MG1655, respectively), as well as an efflux-deficient E. coli strain $(\Delta tolC, \text{ [W5503]})$. While compounds (\pm) -4, (\pm) -5, (\pm) -6, and (\pm) -9 all had reduced antibacterial activity against E. coli MG1655 relative to Debio-1452-NH3, compounds 2, (±)-3, (\pm) -7, and (\pm) -8 maintained good activity (Figure 2) and were thus chosen for further evaluation. A panel of 10 clinical isolates was selected where Debio-1452-NH3 had previously demonstrated only minimal potency (MIC values of 16 or 32 μ g/mL), including two *E. coli*, four *K. pneumoniae*, and four *A*. baumannii strains.¹⁹ As expected, Debio-1452 has no activity against this Gram-negative "challenge panel", and Debio-1452-NH3 has only minimal activity (Figure 2). Assessment of 2, (\pm) -3, (\pm) -7, and (\pm) -8 revealed more potent activity for all



L a l car	Reference strains			E. coli		K. pneumoniae				A. baumannii			
	S. aureus 29213	<i>E. coli</i> ∆tolC	<i>E. coli</i> MG1655	AR-0085	AR-0048	AR-0066	AR-0113	AR-0560	BAA-2472	AR-0033	AR-0273	AR-0299	AR-0313
Debio-1452	0.008	0.062	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32	>32
Debio-1452-NH3	0.031	0.062	4	16	32	32	32	32	16	32	32	32	32
2	0.016	0.031	4	4	8	8	16	16	8	8	8	16	16
$(\pm)-3 \qquad \qquad$	0.016	0.062	4	16	16	8	16	8	8	16	16	16	32
(±)-4	0.031	0.125	16										
(±)-5	0.016	0.062	16										
(±)-6	0.031	0.062	16										
(±)-7	0.016	0.031	4	4	4	8	8	8	8	4	8	4	8
(±)8	0.031	0.125	8	8	16	32	32	16	32	16	32	32	>32
(±)-9	0.062	0.125	32										
(R)-7	0.125	0.5	64	128	128	>128	>128	>128	>128	>128	>128	>128	>128
(S)-7, fabimycin	0.004	0.016	2	1	2	4	4	4	4	4†	4	2†	4 †
	0.002	0.031	8	8	8	32	32	>32	16	16	16	16	16
(S)-11	0.016	0.125	8	8	16	64	32	32	32	64	8	8	64

Figure 2. Debio-1452 analogue synthesis and antibacterial activity. The general synthetic route utilized to synthesize amine-containing compounds, and their antimicrobial activities against Gram-positive and Gram-negative bacteria. (†) indicates dose-independent trailing growth observed; see Supporting Information, Extended Data Figure S1. MIC values were determined using the microdilution broth method, as outlined by CLSI. All experiments were performed in biological triplicate. *E. coli* $\Delta tolC = JW5503$.

four compounds relative to Debio-1452-NH3, with the ε caprolactam (±)-7 emerging as a promising candidate. This compound possessed superior activity against the clinical isolate challenge panel with all strains inhibited at $\leq 8 \ \mu g/mL$. Two derivatives were constructed where the amine-decorated ε -caprolactam was coupled to alternative ring systems, substituting out the benzofuran, but neither of these compounds provided an improvement in activity (Extended Data, Figure S2).

Table 1. Spectrum of Fabimycin Activity^a

Commensal bacteria		Streptococcus pneumoniae		Vancomycin Enterococc		Pseudomonas a	eruginosa	Reference strains		
Species	MIC (µg/mL)	Species	MIC (µg/mL)	Species	MIC (µg/mL)	Species	MIC (µg/mL)	Species	MIC (µg/mL)	
Enterococcus faecalis KLE 2341	>128	ATCC 49619	>128	ATCC 29212	128	ATCC 27853	>128	S. aureus 29213	0.004	
Streptococcus salivarius KLE 2370	>128	MD77773	>128	ATCC 1593	128	AR-0609	>128	E. coli MG1655	2	
Streptococcus parasanguinis KLE 2375	128	MD77841	>128	ATCC 1768	>128	AR-0610	>128	<i>A. baumannii</i> 19606	2	
Bifidobacterium longum ATCC BAA999	>128	CO314937	>128	ATCC 2431	>128	AR-0229	>128	K. pneumoniae BAA-2472	4	
Lactobacillus reuteri ATCC 23272	64	202-7382	>128	ATCC 2059	64	AR-0230	>128			
Blautia producta ATCC 27340	>128	NYO5984	>128	ATCC 2574	>128	AR-0231	>128			
Faecalibacterium prausnitzii ATCC 27768	>128	NYO5986	>128	ATCC 3053	64	AR-0232	>128			
Bacteroides fragilis ATCC 25285	>128	202-5872	>128	ATCC 3183	64	AR-0233	>128			
Bacteroides vulgatus KLE 2303	>128	202-6154	>128	ATCC 3190	>128	AR-0234	>128			
Bacteroides cellulosilyticus KLE 2342	>128	202-6515	>128	ATCC 3191	128	AR-0235	>128			
Stenotrophomonas maltophilia ATCC 13637	128									

^{*a*}MIC experiments with commensal bacteria and pathogenic bacteria possessing alternate enoyl-acyl carrier protein reductases^{29,31,36} indicate these strains are not susceptible to fabimycin.




Figure 3. Optimized synthesis of fabimycin. The synthetic route used to access gram-scale quantities of fabimycin, utilizing dynamic kinetic resolution (DKR) to install the critical stereogenic center.

The two enantiomers of (\pm) -7 were separated by chiral preparatory HPLC, and biological assessment revealed the (-) enantiomer to possess significantly greater antibacterial activity than the (+) enantiomer. X-ray crystallography studies, described later herein, were used to determine that the highly active (-) enantiomer possesses the S stereochemical configuration. As shown in Figure 2, (S)-7, coined

fabimycin,^{25–27} has outstanding activity against *S. aureus* and *E. coli* Δ *tolC*, an MIC value of 2 μ g/mL against *E. coli* MG1655, and very good activity against the clinical isolate challenge panel, whereas (**R**)-7 is significantly less active.

To probe the influence of the amine on antibacterial activity and compound accumulation, two additional derivatives were synthesized: compound **10**, with the expanded ring system but




Figure 4. Antimicrobial activity of fabimycin against clinical isolates. (A) The susceptibility of clinical isolates (Gram-negative species and *S. aureus*) to fabimycin, Debio-1452-NH3, and Debio-1452. MICs performed in biological triplicate. (B) Further exploration of the breadth of fabimycin's antibacterial activity against diverse clinical isolate panels of *K. pneumoniae* and *A. baumannii*, as compared to levofloxacin. MICs performed in biological duplicate.

lacking the amine, and compound (S)-11, a carbamylated version of fabimycin. Of note, 10 and (S)-11 both lack a primary amine. While both compounds display modest inhibition of purified bacterial FabI (Extended Data, Figure S3) and excellent antimicrobial activity against reference strains, they have diminished activity against Gram-negative clinical isolates (Figure 2). Furthermore, when assessed in a whole-cell accumulation assay²⁸ in *E. coli*, 10 displayed reduced whole-cell accumulation consistent with its reduction in antibacterial activity (Extended Data, Figure S4). In contrast, other amine-containing compounds in Figure 2 show significant whole-cell accumulation in *E. coli* (Extended Data,

Figure S4) (the limited aqueous solubility of (S)-11 prevented it from being assessed in this assay).

An interesting aspect of FabI as an antibacterial target is the possibility for a relatively narrow spectrum of activity when compared to that observed with most antibiotics (e.g., inhibitors of protein synthesis, DNA replication, and/or cell wall biosynthesis). For example, it has been noted that ESKAPE pathogen *P. aeruginosa* possesses the FabV isoform, meaning inhibition of FabI will not be lethal in this pathogen.²⁹ Certain Gram-positive pathogens (*Streptococcus sp.*) and commensal bacteria are also not reliant on FabI and thus are expected to be insensitive to FabI inhibition, suggesting that FabI inhibitors could be micro-




Figure 5. Fabimycin mode of action studies. (A) Spontaneous resistance frequencies of *S. aureus, E. coli*, and *A. baumannii* versus fabimycin. Data represent three replicates for each pathogen with error bars representing the SEM. (B) Point mutations in FabI observed in fabimycin-resistant colonies, and the corresponding MIC values of fabimycin versus the mutants. All MICs were performed in biological triplicate.

biome-sparing.^{30–32} To explore this possibility, fabimycin was assessed against a panel of pathogens possessing alternate enoyl-acyl carrier protein reductases as well as anaerobic human commensal bacterial species.^{33–35} In all cases, low/no antibacterial activity was observed against the strains assessed (n = 41), demonstrating the specificity of this FabI inhibitor and its potential for minimal perturbation of the microbiome (Table 1).

Given its promising antibacterial activity, fabimycin was advanced through a battery of mechanistic and translational experiments. While separation of (\pm) -7 on a preparative chiral column was suitable to obtain the quantities of fabimycin required for studies such as MIC assays, it was necessary to optimize the synthetic route to enable scale-up and obtain quantities of the fabimycin required for detailed *in vivo* tolerability, pharmacokinetic analysis, and efficacy experiments. To this end, the synthetic route shown in Figure 3 was developed and employed to generate gram-scale quantities of enantiopure fabimycin.

The route proceeds through condensation of quinolone 12 with hydroxylamine, followed by activation of the resulting oxime (13) via treatment with mesyl chloride to generate compound 14 in good yield. After forming azepanone 15 through a Beckmann rearrangement, molecular bromine was used to produce aryl bromide 16. Alpha-iodination of 16 provided dihalogenated 17 in good yield, and compound 17 was subjected to azidation and subsequent Staudinger reduction to afford amine 18. This amine was the key intermediate for enantioenrichment via a dynamic kinetic resolution (DKR), proceeding through epimerization of the amine via imine formation with 2-hydroxy-5-nitrobenzalde-hyde followed by selective crystallization with L-pyroglutamic acid.³⁷ Optimization of this critical step involved significant screening (Extended Data, Figure S5). After enantioenrich-

ment (up to 99.5% *ee*), amine **19** was protected to afford compound **20** (*ee* maintained) and used in a Heck coupling with acrylic amide **1** to produce **11**, which, when subjected to acidic conditions, liberated fabimycin.

Fabimycin was assessed for its antibacterial activity against a panel of multidrug-resistant *A. baumannii, E. coli,* and *K. pneumoniae* clinical isolates (54 strains in total). As shown in Figure 4A, fabimycin is markedly more potent than Debio-1452 and Debio-1452-NH3 against all the Gram-negative clinical isolates. All three compounds also maintain high potency versus panels of *S. aureus* clinical isolates (Figure 4A and Extended Data, Figure S6).

As the greatest improvement in activity of fabimycin (relative to Debio-1452-NH3) was against K. pneumoniae and A. baumannii clinical isolates, fabimycin was further assessed against more diverse and expansive clinical isolate panels of these two pathogens to determine the MIC₅₀ and MIC₉₀ values. Excitingly, when assessed against a panel of 100 K. pneumoniae clinical isolates, fabimycin inhibited 90% of the strains at 4 μ g/mL, relative to 32 μ g/mL for levofloxacin (Figure 4B). Also encouraging was the narrow MIC range for fabimycin, suggesting that intrinsic resistance to this compound is not prevalent in existing bacterial populations. The analogous data in 100 A. baumannii clinical isolates, a panel specifically curated to represent the genomic diversity of the species³⁸ including 27 multidrug-resistant strains, 35 extensively drug-resistant strains, and 1 pan-resistant strain (fabimycin MIC = 1 μ g/mL), are also promising, with fabimycin exhibiting a MIC_{90} value of 8 μ g/mL (relative to 32 μ g/mL for levofloxacin) and a narrow distribution of MIC values (Figure 4B).

Mode of Action. Spontaneous resistant mutants to fabimycin were generated in *E. coli* MG1655, *A. baumannii* 19606, and *S. aureus* ATCC 29213 at 8×, 16×, and 32× the




Figure 6. Co-crystal structures of fabimycin and its enantiomer with FabI. (A) Co-crystal structure of fabimycin with *E. coli* FabI with NADH cofactor (PDB 7UMW). (B) Co-crystal structure of (\mathbf{R})-7 in *E. coli* FabI with NADH cofactor (7UM8). (C) Water network surrounding fabimycin in the *E. coli* FabI active site. (D) Water network surrounding (\mathbf{R})-7 in the *E. coli* FabI active site.

respective MICs with low frequencies of resistance observed at $8 \times -16 \times$ the MIC for all pathogens (Figure 5A). Importantly, sequencing of the *fabI* gene in resistant colonies revealed mutations encoding single amino acid changes within the active site of FabI (Figure 5B). While several FabI mutations were observed in fabimycin-resistant A. baumannii, the MIC of the bacteria harboring mutant FabI was often near fabimycin concentrations attained in vivo (as shown later). In E. coli, the most frequently observed FabI mutation to arise in fabimycinresistant colonies was at G148 (Figure 5B); E. coli with mutations at this position in FabI have been previously shown to have attenuated fitness.¹⁹ Encouragingly, the mutant prevention concentration (MPC, the concentration where no resistant mutants are observed) of fabimycin versus E. coli was found to be 64 μ g/mL and, impressively, in *S. aureus*, the MPC was 0.125 µg/mL. A serial passaging experiment of E. coli MG1655 in the presence of a subinhibitory concentration of fabimycin over the course of 21 days led to an 8-fold increase in the MIC for fabimycin, relative to a 128-fold increase in the

MIC of ciprofloxacin in the same experiment (Extended Data, Figure 7A). To investigate the rate of killing, a time-kill growth curve was generated that revealed fabimycin slowly kills *E. coli* over the course of 8 h (Extended Data, Figure 7B); however, fabimycin was not profoundly bactericidal in this experiment, mimicking its progenitor's (Debio-1452) behavior in *S. aureus.*²¹

Crystallography, Molecular Dynamics, and Biophysics. An interesting feature of fabimycin is its considerably enhanced antibacterial activity relative to its enantiomer (\mathbf{R})-7. Assessment in *E. coli* reveals that each enantiomer accumulates intracellularly to a similar extent (Extended Data, Figure S4). In contrast, evaluation of the two enantiomers in the FabI activity assay shows a significant differential between the two enantiomers (Extended Data, Figure S8), with fabimycin being at least five-fold more potent against *A. baumannii* and *E. coli* FabI. Of note, in this enzyme assay IC₅₀ values cannot be accurately determined below ~10 nM, so the value for fabimycin likely under-represents its biochemical potency.




Figure 7. Computational and biophysical evaluation of fabimycin and its enantiomer. (A) Molecular dynamic simulations of fabimycin and its enantiomer using the co-crystal structures in *E. coli* FabI, demonstrating the enhanced flexibility (decreased stability) of (R)-7. (B) The determined enthalpy changes upon binding to FabI as assessed by isothermal titration calorimetry (ITC), as well as observed stabilization in a differential scanning fluorimetry assay of FabI (from *E. coli* and *A. baumannii*) upon compound binding relative to the holoenzyme. T_m values are means of technical triplicates with error shown as the standard deviation.

Taken together, the data suggest that the diminished antibacterial activity of (R)-7 relative to fabimycin is due to reduced target engagement and not differential intracellular accumulation.

To further investigate the molecular basis for the observed differential activity between enantiomers, X-ray crystal structures of fabimycin and its enantiomer (R)-7 bound to both E. coli and A. baumannii FabI with NADH cofactor were solved with resolutions ranging from 1.5 to 2.7 Å. The general binding mode of the compounds is similar to what has been previously reported for this class of compounds and Debio-1452 in particular.³⁹ In complex with E. coli FabI, the pyridoazepanone ring forms two hydrogen bonds with the backbone carbonyl and amide nitrogen of conserved residue Ala95 (Figure 6A,B). A water-mediated interaction is also observed between the carbonyl of the lactam and the backbone amide of Gly97. Additionally, a hydrogen bond is formed between the acrylamide linker carbonyl and the conserved residue Tyr156. The benzopyran ring is nestled in a hydrophobic pocket formed by conserved, hydrophobic residues Tyr146, Pro191, Ile153, Met206, and Phe203.

Similar to *E. coli*, the hydrogen-bonding network of the pyridoazepanone ring, interactions of the acrylamide carbonyl, and the position of the flanking benzofuran ring are maintained with the analogous amino acid residues in *A. baumannii* FabI (Extended Data, Figure S9A,B). While no significant changes of the interacting residues can be seen between fabimycin and (*R*)-7 in *A. baumannii* FabI, the enhanced resolution of the *E. coli* crystal structures captures a more nuanced and detailed binding mode. In the *E. coli* structure, a large water network is observed between the ligand, NADH cofactor, and FabI enzyme. While this network exists in the binding of both enantiomers, it is larger and more tightly structured in the fabimycin co-crystal (see Figure 6C,D).

Intrigued by the relative similarity of the crystal structures, experiments were conducted to evaluate the stability and

dynamics of the inhibitor-enzyme complex as well as the strain energy of each enantiomer. The established E. coli co-crystal structure was utilized for computational studies which determined that the less active (R)-enantiomer is more strained relative to fabimycin (~8.30 kcal/mol higher) in the active site. This is reflected in molecular dynamic simulations that reveal the (R)-enantiomer to be much more flexible in the binding pocket of FabI leading to overall less-productive hydrogen-bond interactions with critical surrounding residues such as Ala95 and Tyr156 (Figure 7A). Isothermal titration calorimetry (ITC) was used to confirm the nanomolar potency of each compound and showed a doubling in enthalpy for fabimycin relative to the less active enantiomer (Figure 7B). Finally, differential scanning fluorimetry (DSF) experiments show that fabimycin enhances the stability of the enzymeinhibitor complex significantly more than the less active enantiomer in both E. coli and A. baumannii versions of FabI (Figure 7B).

In Vivo Experiments. Given the low resistance frequency and promising data with >200 Gram-negative clinical isolates, experiments were conducted to probe the suitability of fabimycin for in vivo infection models. As a prelude to these studies, fabimycin was evaluated against three human cell lines (HFF-1, A549, HepG2) and for its ability to lyse human red blood cells. These studies revealed fabimycin to be less cytotoxic relative to Debio-1452-NH3 and nonhemolytic even at high concentrations (200 μ M, Extended Data, Table S1). Fabimycin also has lower activity against the hERG ion channel relative to both Debio-1452 and Debio-1452-NH3, and lower plasma protein binding relative to Debio-1452 (Extended Data, Table S1). Formulation and MTD studies were performed, and in all cases fabimycin was found to be better tolerated in mice with an MTD of >200 mg/kg (IP injection) relative to 50 mg/kg for Debio-1452-NH3 (Extended Data, Table S2).




Figure 8. Plasma stability and *in vivo* efficacy of fabimycin. (A) Assessment of fabimycin stability in plasma. Data shown as the mean and standard deviation from two experiments. (B) Acute pneumonia infections initiated in CD-1 mice with *A. baumannii* AR-0299 (1.6×10^8 CFUs per mouse intranasally). Mice were treated with vehicle (8 mice) or FabI inhibitor (8 mice per group) 4, 23, and 41 h postinfection (50 mg/kg intramuscular) and the bacterial burden evaluated at 48h postinfection. (C) Neutropenic mouse thigh infection initiated in CD-1 mice with *A. baumannii* AR-0299 (1.22×10^6 CFUs per mouse intramuscular in thigh) were treated with vehicle (8 mice) or FabI inhibitor (8 mice) or FabI inhibitor (8 mice) per group) 2, 6, and 11 h postinfection (50 mg/kg intramuscular), and the bacterial burden was evaluated 26h postinfection. (D) Neutropenic mouse thigh infection initiated in CD-1 mice with *S. aureus* USA300 LAC (2.3×10^6 CFU per mouse intramuscular in thigh) were treated with vehicle (eight mice) or FabI inhibitor (eight mice per group) 2 and 7 h postinfection (5 mg/kg retro-orbital IV), and the bacterial burden was evaluated 24 h postinfection. Debio-1452-tosylate used. FabI inhibitors formulated with 20% SBE- β -CD in H₂O. In B, C, and D statistical significance was determined by one-way ANOVA with Tukey's multiple comparisons. NS, not significant. ****P < 0.0001. Error bars represent standard deviation.

An interesting aspect of this compound class is the metabolic instability in mice leading to suboptimal pharmacokinetics;²⁴ indeed, assessment of fabimycin in mouse, rat, and human plasma showed considerable instability in mouse plasma contrasted with excellent stability in rat and human plasma (Figure 8A). While this data suggests the possibility that antibacterial activity could improve as fabimycin moves toward humans, it does complicate the evaluation of this compound class in murine infection models. Thus, as a prelude to efficacy experiments in mouse infection models, a pharmacokinetic study was conducted with fabimycin using neutropenic female BALB/c mice infected with drug-resistant *A. baumannii* (fabimycin MIC = 2 μ g/mL) where single doses of the compound (20, 50, 75, 100 mg/kg) were administered intravenously to the infected mice and blood taken over the course of 8 h. Encouragingly, when dosed at 75 mg/kg, fabimycin concentrations stayed above the MIC for the infectious strain for over 6 h in the thigh tissue with the C_{max} nearing the MPC for wild-type *E. coli* when dosed at 100 mg/kg (Extended Data, Figure S10).

With formulation, MTD, and pharmacokinetic data in hand, the efficacy of fabimycin was evaluated in murine infection




Figure 9. In vivo efficacy of fabimycin in a murine UTI model. After inducing diuresis, infection initiated in C3H/HeJ mice (8 per arm, 1.38×10^9 CFU/mouse transurethral) with *E. coli* AR-0055 and treated with fabimycin (IV) at varying concentrations three times daily with bacterial enumeration at 168h postinfection. Fabimycin formulated in 17% Cremophor EL, 3% SBE- β -CD in H₂O which was the formulation used in the vehicle arm (administered intravenously on the same schedule as fabimycin). Colistin was formulated in H₂O with 0.9% NaCl and administered subcutaneously. Percentage in red indicates the percentage of animals with bacterial counts below the limit of detection (LOD, indicated by the dotted horizontal line). In A—D statistical significance was determined by one-way ANOVA with Tukey's multiple comparisons. NS, not significant. **P* = 0.0243, ****P* < 0.001, *****P* < 0.0001. Data represented as the mean with s.e.m.

models. To start, a comparative assessment was made of fabimycin and Debio-1452-NH3 in two murine infection models using a dosing regimen (50 mg/kg, intramuscular) near the MTD for Debio-1452-NH3 but well below the MTD for

fabimycin. Using an extensively drug-resistant *A. baumannii* clinical isolate, fabimycin outperformed Debio-1452-NH3 in both lung and neutropenic thigh infection models and achieved a >3-fold decrease in log(CFU/lung) and >2-fold

decrease log(CFU/thigh) relative to the vehicle (Figure 8B,C). In a S. aureus (MRSA clinical isolate) neutropenic thigh infection model fabimycin showed significantly greater reduction of bacterial burden relative to Debio-1452 when both were administered at the low dose of 5 mg/kg (Figure 8D). As the goal of these initial models was simply to assess efficacy compared to progenitor compounds, fabimycin dosing was not maximized or optimized. To address this, fabimycin was evaluated in an experiment where neutropenic, A. baumannii-infected mice were treated four times a day (via IV injection) with doses spanning 1.25-75 mg/kg. In this experiment, significant dose-dependent responses were observed beginning at 30 mg/kg (Extended Data, Figure S11A). When using the most efficacious dose (75 mg/kg, four times a day) in a murine neutropenic thigh infection experiment with an extensively resistant NDM-1 containing strain of A. baumannii, fabimycin was able to reduce bacterial burden by nearly 2 log(CFU/thigh) (Extended Data, Figure S11B).

With an effective dose established, we aimed to evaluate fabimycin in a murine model of an infection with high translational value. Urinary tract infections (UTIs) represent one of the biggest risks for healthy individuals in terms of exposure to antibiotic-resistant bacteria with many individuals contracting one in their lifetime (roughly 1 in 2 women and 1 in 10 men);⁴⁰ UTIs caused by Gram-negative pathogens, particularly those that are drug-resistant, are becoming more frequent and remain a major clinical challenge.⁴⁰⁻⁴² As E. coli is the causative agent in the vast majority of UTIs,⁴³ fabimycin was evaluated in a murine UTI model with a challenging, extensively drug-resistant strain of carbapenem-resistant E. coli (fabimycin MIC = 2 μ g/mL). When intravenously dosed at 33.3 mg/kg, three times a day, fabimycin was able to achieve 3.0, 2.8, 2.9, and 1.9 \log_{10} reductions in bacterial load relative to the vehicle in the spleen, bladder, liver, and kidney tissues, respectively (Figure 9). Dose fractionation studies in infected mice also revealed other dosing regiments to be effective in reducing the bacterial load to a significant extent in mouse tissue (Figure 9 and Extended Data, Figure S12).

DISCUSSION

There is a rich history in antibacterial drug discovery of identifying and advancing chemical matter arising from wholecell phenotypic screens. In contrast, while biochemical screens have uncovered a wealth of scaffolds with promising activity, there has typically been less interest in such compounds due to the documented inability to imbue them with whole-cell antibacterial activity.^{12,13} In this context, Debio-1452 is an interesting case study as it was developed from a progenitor compound that had only biochemical FabI inhibitory activity—it was first converted into a *S. aureus*-specific drug (Debio-1452), then to Debio-1452-NH3, and now into fabimycin, which possesses promising activity against important Gram-negative pathogens.

Relative to Debio-1452-NH3, fabimycin has significantly improved activity against *A. baumannii*, even surpassing the potency increase observed versus *E. coli*, consistent with the notion that certain FabI inhibitors can be tuned for specific bacterial homologues of FabI if the creation of pathogenspecific antibiotics is of interest.¹⁴ The generated X-ray cocrystal structures of fabimycin bound to *A. baumannii* and *E. coli* FabI reveal that key hydrogen-bonding interactions are conserved between the two forms of the enzyme, but no significant protein conformational differences in the active site.

Given the limitations of the FabI enzymatic assay when evaluating compounds possessing low nanomolar potency, use of multiple biochemical techniques will be critical to the understanding of current and future FabI inhibitors. Overall, a combination of biochemical, structural, biophysical, and computational approaches was used to better understand the differences in whole-cell activity of fabimycin and (R)-7. Biochemical assessment of the inhibitory activities of fabimycin and (R)-7 showed modest differences in potency against purified E. coli FabI (4.75-fold), whereas the differences in MIC activity between the two enantiomers in Gram-negative clinical isolates is much more significant (64-128 fold). Comparison of the co-crystal structures of fabimycin and (R)-7 reveals a more expansive and tightly structured water network in the fabimcyin structure. This result is consistent with ITC data showing fabimycin to have a more favorable binding entropy, DSF results showing a larger change in melting temperature upon compound binding to FabI relative to the less-active (R)-7, and with molecular dynamic simulations showing fabimycin to be much less strained (i.e., more stable) in the E. coli FabI active site. Taken together, these results suggest that the differences in whole-cell activity between the two enantiomers is primarily due to a more favorable water interaction network and higher degree of protein and ligand stability for fabimycin.

Beyond Gram-negative activity, the ability of fabimycin to retain approximately equivalent activity as Debio-1452 against *S. aureus* is impressive, as Debio-1452 was optimized to treat *S. aureus* infections and has thus set a high bar for potency versus this pathogen, both *in vitro* and *in vivo*.^{17,44,45} The very low frequency of resistance $(1.8 \times 10^{-10} \text{ to } 5.2 \times 10^{-10}, \text{ likely due}$ at least in part to critical interactions with the amide backbone of FabI),^{14,46} outstanding performance in the serial passage experiment, and the extremely low mutation prevention concentration (0.125 µg/mL) suggest great promise for fabimycin against *S. aureus*, as the MPC is dwarfed by the concentration of fabimycin achieved in mouse plasma ($C_{\text{max}} = 47 \ \mu\text{g/mL}, t_{1/2} = 1.4 \text{ h}$).

Inhibition of FabI is attractive due to its orthogonality (relative to the mammalian fatty acid biosynthetic analogue) and its essential nature, for certain bacteria, in the maintenance of cellular membranes.^{47,48} The nature of the FabI target is such that its inhibition will not be lethal to all types of bacteria, as many bacteria have redundant enzymes or can compensate by exogenous fatty acid uptake;³⁰ indeed, fabimycin has virtually no whole-cell activity versus a sampling of such species. While this includes some pathogenic bacteria, such as P. aeruginosa, it also includes many commensal bacteria, suggesting that a suitable FabI inhibitor could be less damaging to the gut microbiome than the typical broad-spectrum antibiotic.³² In this vein, the activity of fabimycin against UTIs is very promising, given how antibiotic treatment of UTIs is known to trigger *Clostridioides difficile* infection⁴⁹ and the recently described "gut-bladder axis" in recurrent UTIs.^{50,51}

Similar to fusidic acid and some other antibiotics,^{52,53} the advancement of this class of FabI inhibitors has been complicated by the uniquely poor stability of these compounds in mouse plasma. Given the promising activity of fabimycin in mouse infection models and encouraging data that fabimycin is dramatically more stable in rat and human plasma, it is reasonable to believe that fabimycin efficacy may improve as it is used to treat infections in higher organisms. The potency of fabimycin, combined with the very low resistance frequency and apparent lack of pre-existing resistance, bodes well for its translation.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acscentsci.2c00598.

Supporting figures and tables, materials and methods, experimental procedures, and characterization of chemical products including LCMS traces and NMR (¹H, ¹³C) spectra (PDF)

AUTHOR INFORMATION

Corresponding Author

Paul J. Hergenrother – Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States;
orcid.org/0000-0001-9018-3581; Email: hergenro@ illinois.edu

Authors

- Erica N. Parker Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0001-5982-0458
- Brett N. Cain Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States
- Behnoush Hajian Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
- Rebecca J. Ulrich Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0001-6013-6565
- Emily J. Geddes Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States
- Sulyman Barkho Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
- Hyang Yeon Lee Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States
- John D. Williams Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
- Malik Raynor Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
- Diana Caridha Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
- Angela Zaino Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States

Mrinal Shekhar – Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States

Kristen A. Muñoz – Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States

Kara M. Rzasa – Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States

Emily R. Temple – Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States

Diana Hunt – Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States; Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts 02115, United States

- Xiannu Jin Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
- Chau Vuong Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
- Kristina Pannone Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States

Aya M. Kelly – Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States

- Michael P. Mulligan Department of Chemistry and Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States
- Katie K. Lee Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
- Gee W. Lau Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana–Champaign, Urbana, Illinois 61801, United States; orcid.org/0000-0002-7962-3950
- **Deborah T. Hung** Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States; Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts 02115, United States; • orcid.org/0000-0003-4262-0673

Complete contact information is available at: https://pubs.acs.org/10.1021/acscentsci.2c00598

Author Contributions

[#]E.N.P. and B.N.C. contributed equally.

Notes

The authors declare the following competing financial interest(s): The University of Illinois and the Broad Institute have filed patents on some compounds described herein.

ACKNOWLEDGMENTS

This work was supported by the University of Illinois and the NIH (AI136773 to P.J.H. and G.W.L.). K.A.M. and M.P.M. are members of the NIH Chemistry-Biology Interface Training Grant (T32-GM136629). R.J.U. is supported by an NIH Ruth Kirschstein Award (F31AI161953) and was an NSF predoctoral fellow. This work utilized NIAID's suite of preclinical services for in vitro and in vivo assessment (Contract Numbers HHSN272201700020I 75N93021F00001, HHSN272201700020I 75N93021F00002, and 75N93019D00022 75N93020F00001). The Collaborative Hub for Early Antibiotic Discovery (CHEAD) is grateful for financial support from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This work was supported by a gift from Anita and Josh Bekenstein and by funding provided under Cooperative Agreement #IDSEP160030-01-00 from Biomedical Advanced Research and Development Authority (BARDA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of The Assistant Secretary for Preparedness and Response. This project has been funded in part by federal funds from the Military Infectious Disease Research Program Proposals MI210200 and MI220020. We

thank L. Li (Metabolomics Center, Roy J. Carver Biotechnology Center, UIUC) for LC-MS/MS analysis. We thank Dean Olson, Lingyang Zhu, and N. Duay at the School of Chemical Sciences NMR Laboratory at UIUC for NMR services. The Bruker 500 MHz NMR spectrometer was obtained with the financial support of the Roy J. Carver Charitable Trust, Muscatine, Iowa.

REFERENCES

(1) Konychev, A.; Heep, M.; Moritz, R. K.; Kreuter, A.; Shulutko, A.; Fierlbeck, G.; Bouylout, K.; Pathan, R.; Trostmann, U.; Chaves, R. L. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. *Drugs Aging* **2013**, *30* (10), 829–836.

(2) Moran, G. J.; Fang, E.; Corey, G. R.; Das, A. F.; De Anda, C.; Prokocimer, P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* **2014**, *14* (8), 696–705.

(3) File, T. M.; Goldberg, L.; Das, A.; Sweeney, C.; Saviski, J.; Gelone, S. P.; Seltzer, E.; Paukner, S.; Wicha, W. W.; Talbot, G. H.; Gasink, L. B. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. *Clin Infect Dis* **2019**, *69* (11), 1856– 1867.

(4) WHO Antibacterial products in clinical development for priority pathogens. https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens (accessed June 13, 2022).

(5) Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect Dis 2008, 197 (8), 1079-81.

(6) Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis* **2009**, *48* (1), 1–12.

(7) Cassini, A.; Hogberg, L. D.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Simonsen, G. S.; Colomb-Cotinat, M.; Kretzschmar, M. E.; Devleesschauwer, B.; Cecchini, M.; Ouakrim, D. A.; Oliveira, T. C.; Struelens, M. J.; Suetens, C.; Monnet, D. L.; the Burden of AMR Collective Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect. Dis.* **2019**, *19* (1), 56–66.

(8) Antimicrobial Resistance, C.. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022, 399 (10325), 629–655.

(9) Richter, M. F.; Drown, B. S.; Riley, A. P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J. Predictive compound accumulation rules yield a broad-spectrum antibiotic. *Nature* **2017**, *545* (7654), 299–304.

(10) Zhao, S.; Adamiak, J. W.; Bonifay, V.; Mehla, J.; Zgurskaya, H. I.; Tan, D. S. Defining new chemical space for drug penetration into Gram-negative bacteria. *Nat. Chem. Biol.* **2020**, *16* (12), 1293–1302.

(11) Munoz, K. A.; Hergenrother, P. J. Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria. *Acc. Chem. Res.* **2021**, *54* (6), 1322–1333.

(12) Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat. Rev. Drug Discov* **2007**, *6* (1), 29–40.

(13) Tommasi, R.; Brown, D. G.; Walkup, G. K.; Manchester, J. I.; Miller, A. A. ESKAPEing the labyrinth of antibacterial discovery. *Nat. Rev. Drug Discov* 2015, 14 (8), 529–42. (14) Yao, J.; Rock, C. O. Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics. *Cold Spring Harb Perspect Med.* **2016**, *6* (3), a027045.

(15) Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; Payne, D. J.; Rittenhouse, S. F.; Moore, T. D.; DeWolf, W. E., Jr.; Keller, P. M.; Qiu, X.; Janson, C. A.; Vaidya, K.; Fosberry, A. P.; Smyth, M. G.; Jaworski, D. D.; Slater-Radosti, C.; Huffman, W. F. Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 2001, 11 (17), 2241-4. (16) Payne, D. J.; Miller, W. H.; Berry, V.; Brosky, J.; Burgess, W. J.; Chen, E.; DeWolf Jr, W. E., Jr.; Fosberry, A. P.; Greenwood, R.; Head, M. S.; Heerding, D. A.; Janson, C. A.; Jaworski, D. D.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Newlander, K. A.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Slater-Radosti, C.; Salyers, K. L.; Seefeld, M. A.; Smyth, M. G.; Takata, D. T.; Uzinskas, I. N.; Vaidya, K.; Wallis, N. G.; Winram, S. B.; Yuan, C. C.; Huffman, W. F. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 2002, 46 (10), 3118-24.

(17) Wittke, F.; Vincent, C.; Chen, J.; Heller, B.; Kabler, H.; Overcash, J. S.; Leylavergne, F.; Dieppois, G. Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid. *Antimicrob. Agents Chemother.* **2020**, *64* (10), e00250-20.

(18) Karlowsky, J. A.; Kaplan, N.; Hafkin, B.; Hoban, D. J.; Zhanel, G. G. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcusspecific spectrum of activity. *Antimicrob. Agents Chemother.* **2009**, *53* (8), 3544–8.

(19) Parker, E. N.; Drown, B. S.; Geddes, E. J.; Lee, H. Y.; Ismail, N.; Lau, G. W.; Hergenrother, P. J. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens. *Nat. Microbiol* **2020**, *5* (1), 67–75.

(20) Richter, M. F.; Hergenrother, P. J. The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics. *Ann. N.Y. Acad. Sci.* **2019**, *1435* (1), 18–38.

(21) Kaplan, N.; Albert, M.; Awrey, D.; Bardouniotis, E.; Berman, J.; Clarke, T.; Dorsey, M.; Hafkin, B.; Ramnauth, J.; Romanov, V.; Schmid, M. B.; Thalakada, R.; Yethon, J.; Pauls, H. W. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. *Antimicrob. Agents Chemother.* **2012**, *56* (11), 5865–5874.

(22) Seefeld, M. A.; Miller, W. H.; Newlander, K. A.; Burgess, W. J.; DeWolf, W. E., Jr.; Elkins, P. A.; Head, M. S.; Jakas, D. R.; Janson, C. A.; Keller, P. M.; Manley, P. J.; Moore, T. D.; Payne, D. J.; Pearson, S.; Polizzi, B. J.; Qiu, X.; Rittenhouse, S. F.; Uzinskas, I. N.; Wallis, N. G.; Huffman, W. F. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. *J. Med. Chem.* **2003**, *46* (9), 1627–35.

(23) Ramnauth, J.; Surman, M. D.; Sampson, P. B.; Forrest, B.; Wilson, J.; Freeman, E.; Manning, D. D.; Martin, F.; Toro, A.; Domagala, M.; Awrey, D. E.; Bardouniotis, E.; Kaplan, N.; Berman, J.; Pauls, H. W. 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI. *Bioorg. Med. Chem. Lett.* **2009**, *19* (18), 5359–5362.

(24) Takhi, M.; Sreenivas, K.; Reddy, C. K.; Munikumar, M.; Praveena, K.; Sudheer, P.; Rao, B. N.; Ramakanth, G.; Sivaranjani, J.; Mulik, S.; Reddy, Y. R.; Narasimha Rao, K.; Pallavi, R.; Lakshminarasimhan, A.; Panigrahi, S. K.; Antony, T.; Abdullah, I.; Lee, Y. K.; Ramachandra, M.; Yusof, R.; Rahman, N. A.; Subramanya, H. Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors. *Eur. J. Med. Chem.* **2014**, *84*, 382– 394.

(25) Hergenrother, P. J.; Geddes, E. J.; Drown, B. S.; Motika, S. E.; Parker, S. E. Antibiotics Effective for Gram-Negative Pathogens. WO2019/177975A1, 2019.

(26) Gerusz, V. B.; Bravo, J.; Pauls, H.; Berman, J.; Finn, T. Novel Compounds and their Use. WO2021/123372A1, 2021.

(27) Hergenrother, P. J.; Parker, E. N.; Hung, D.; Serrano-Wu, M.; Lee, K. K. FabI inhibitors for Gram-negative pathogens. US Provisional Patent Application No. 63/156,145. 2021.

(28) Geddes, E. J.; Li, Z.; Hergenrother, P. J. An LC-MS/MS assay and complementary web-based tool to quantify and predict compound accumulation in E. coli. *Nat. Protoc* **2021**, *16* (10), 4833–4854.

(29) Zhu, L.; Lin, J.; Ma, J.; Cronan, J. E.; Wang, H. Triclosan resistance of Pseudomonas aeruginosa PAO1 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. *Antimicrob. Agents Chemother.* **2010**, *54* (2), 689–698.

(30) Parsons, J. B.; Frank, M. W.; Subramanian, C.; Saenkham, P.; Rock, C. O. Metabolic basis for the differential susceptibility of Grampositive pathogens to fatty acid synthesis inhibitors. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108* (37), 15378–15383.

(31) Zhu, L.; Bi, H.; Ma, J.; Hu, Z.; Zhang, W.; Cronan, J. E.; Wang, H. The two functional enoyl-acyl carrier protein reductases of Enterococcus faecalis do not mediate triclosan resistance. *mBio* **2013**, *4* (5), e00613–13.

(32) Yao, J.; Carter, R. A.; Vuagniaux, G.; Barbier, M.; Rosch, J. W.; Rock, C. O. A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome. *Antimicrob. Agents Chemother.* **2016**, *60* (7), 4264–73.

(33) Imai, Y.; Meyer, K. J.; Iinishi, A.; Favre-Godal, Q.; Green, R.; Manuse, S.; Caboni, M.; Mori, M.; Niles, S.; Ghiglieri, M.; Honrao, C.; Ma, X.; Guo, J. J.; Makriyannis, A.; Linares-Otoya, L.; Bohringer, N.; Wuisan, Z. G.; Kaur, H.; Wu, R.; Mateus, A.; Typas, A.; Savitski, M. M.; Espinoza, J. L.; O'Rourke, A.; Nelson, K. E.; Hiller, S.; Noinaj, N.; Schaberle, T. F.; D'Onofrio, A.; Lewis, K. A new antibiotic selectively kills Gram-negative pathogens. *Nature* **2019**, *576* (7787), 459–464.

(34) Leimer, N.; Wu, X.; Imai, Y.; Morrissette, M.; Pitt, N.; Favre-Godal, Q.; Iinishi, A.; Jain, S.; Caboni, M.; Leus, I. V.; Bonifay, V.; Niles, S.; Bargabos, R.; Ghiglieri, M.; Corsetti, R.; Krumpoch, M.; Fox, G.; Son, S.; Klepacki, D.; Polikanov, Y. S.; Freliech, C. A.; McCarthy, J. E.; Edmondson, D. G.; Norris, S. J.; D'Onofrio, A.; Hu, L. T.; Zgurskaya, H. I.; Lewis, K. A selective antibiotic for Lyme disease. *Cell* **2021**, *184* (21), 5405–5418.

(35) Poyet, M.; Groussin, M.; Gibbons, S. M.; Avila-Pacheco, J.; Jiang, X.; Kearney, S. M.; Perrotta, A. R.; Berdy, B.; Zhao, S.; Lieberman, T. D.; Swanson, P. K.; Smith, M.; Roesemann, S.; Alexander, J. E.; Rich, S. A.; Livny, J.; Vlamakis, H.; Clish, C.; Bullock, K.; Deik, A.; Scott, J.; Pierce, K. A.; Xavier, R. J.; Alm, E. J. A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research. *Nat. Med.* **2019**, *25* (9), 1442–1452.

(36) Marrakchi, H.; Dewolf, W. E., Jr.; Quinn, C.; West, J.; Polizzi, B. J.; So, C. Y.; Holmes, D. J.; Reed, S. L.; Heath, R. J.; Payne, D. J.; Rock, C. O.; Wallis, N. G. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). *Biochem. J.* **2003**, 370 (3), 1055–1062.

(37) Armstrong, J. D.; Eng, K. K.; Keller, J. L.; Purick, R. M.; Hartner, F. W.; Choi, W.-B.; Askin, D.; Volante, R.P. An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one. *Tetrahedron Lett.* **1994**, 35 (20), 3239–3242.

(38) Galac, M. R.; Snesrud, E.; Lebreton, F.; Stam, J.; Julius, M.; Ong, A. C.; Maybank, R.; Jones, A. R.; Kwak, Y. I.; Hinkle, K.; Waterman, P. E.; Lesho, E. P.; Bennett, J. W.; Mc Gann, P. A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development. *Antimicrob. Agents Chemother.* **2020**, *64* (10), e00840-20.

(39) Rao, N. K.; Nataraj, V.; Ravi, M.; Panchariya, L.; Palai, K.; Talapati, S. R.; Lakshminarasimhan, A.; Ramachandra, M.; Antony, T. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies. *Chem. Biol. Drug Des* **2020**, *96* (2), 704–713.

(40) Sihra, N.; Goodman, A.; Zakri, R.; Sahai, A.; Malde, S. Nonantibiotic prevention and management of recurrent urinary tract infection. *Nat. Rev. Urol* **2018**, *15* (12), 750–776.

(41) Flores-Mireles, A. L.; Walker, J. N.; Caparon, M.; Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat. Rev. Microbiol* **2015**, *13* (5), 269–284.

(42) Goebel, M. C.; Trautner, B. W.; Grigoryan, L. The Five Ds of Outpatient Antibiotic Stewardship for Urinary Tract Infections. *Clin Microbiol Rev.* **2021**, *34* (4), e0000320.

(43) Nielubowicz, G. R.; Mobley, H. L. Host-pathogen interactions in urinary tract infection. *Nat. Rev. Urol* **2010**, *7* (8), 430–441.

(44) Flamm, R. K.; Rhomberg, P. R.; Kaplan, N.; Jones, R. N.; Farrell, D. J. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. *Antimicrob. Agents Chemother.* **2015**, *59* (5), 2583–2587.

(45) Hafkin, B.; Kaplan, N.; Murphy, B. Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities. *Antimicrob. Agents Chemother.* **2016**, *60* (3), 1695–701.

(46) Radka, C. D.; Rock, C. O. Mining Fatty Acid Biosynthesis for New Antimicrobials. *Annu. Rev. Microbiol.* **2022**, *76*, DOI: 10.1146/annurev-micro-041320-110408

(47) Payne, D. J.; Warren, P. V.; Holmes, D. J.; Ji, Y.; Lonsdale, J. T. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. *Drug Discov Today* **2001**, *6* (10), 537–544.

(48) Yao, J.; Rock, C. O. Bacterial fatty acid metabolism in modern antibiotic discovery. *Biochim Biophys Acta Mol. Cell Biol. Lipids* **2017**, *1862* (11), 1300–1309.

(49) Staley, C.; Vaughn, B. P.; Graiziger, C. T.; Sadowsky, M. J.; Khoruts, A. Gut-sparing treatment of urinary tract infection in patients at high risk of Clostridium difficile infection. *J. Antimicrob. Chemother.* **2017**, 72 (2), 522–528.

(50) Worby, C. J.; Schreiber, H. L. t.; Straub, T. J.; van Dijk, L. R.; Bronson, R. A.; Olson, B. S.; Pinkner, J. S.; Obernuefemann, C. L. P.; Munoz, V. L.; Paharik, A. E.; Azimzadeh, P. N.; Walker, B. J.; Desjardins, C. A.; Chou, W. C.; Bergeron, K.; Chapman, S. B.; Klim, A.; Manson, A. L.; Hannan, T. J.; Hooton, T. M.; Kau, A. L.; Lai, H. H.; Dodson, K. W.; Hultgren, S. J.; Earl, A. M. Longitudinal multiomics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women. *Nat. Microbiol* **2022**, 7 (5), 630–639.

(51) Schembri, M. A.; Nhu, N. T. K.; Phan, M. D. Gut-bladder axis in recurrent UTI. *Nat. Microbiol* **2022**, 7 (5), 601–602.

(52) Njoroge, M.; Kaur, G.; Espinoza-Moraga, M.; Wasuna, A.; Dziwornu, G. A.; Seldon, R.; Taylor, D.; Okombo, J.; Warner, D. F.; Chibale, K. Semisynthetic Antimycobacterial C-3 Silicate and C-3/C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma, and Mycobacterium tuberculosis culture. ACS Infect Dis **2019**, 5 (9), 1634–1644.

(53) Smith, P. W.; Zuccotto, F.; Bates, R. H.; Martinez-Martinez, M. S.; Read, K. D.; Peet, C.; Epemolu, O. Pharmacokinetics of beta-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future. *ACS Infect Dis* **2018**, *4* (10), 1439–1447.